A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With BRCA Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Ovarian Cancer|Breast Cancer
Interventions: DRUG: Olaparib tablets, 150 mg|DRUG: Lynparza® (olaparib) tablets 150 mg
Sponsor: Sandoz